Redefining clinical outcomes and endpoints in glaucoma

References

• Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221-e1234.
   Web of Science ®Google Scholar
• Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13; discussion 829–30.
   Google Scholar
• Palmer JJ, Chinanayi F, Gilbert A, et al. Trends and implications for achieving VISION 2020 human resources for eye health targets in 16 countries of sub-Saharan Africa by the year 2020. Hum Resour Health. 2014;12:45.
   PubMed Web of Science ®Google Scholar
• Kyari F, Abdull MM, Bastawrous A, et al. Epidemiology of glaucoma in Sub-Saharan Africa: prevalence, incidence and risk factors. Middle East Afr J Ophthalmol. 2013;20:111–125.
   PubMedGoogle Scholar
• Court JH, Austin MW. Virtual glaucoma clinics: patient acceptance and quality of patient education compared to standard clinics. Clin Ophthalmol. 2015;9:745–749.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
   PubMed Web of Science ®Google Scholar
• De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials. 2001;22:485–502.
   PubMedGoogle Scholar
• Partin AW, Hanks GE, Klein EA, et al. Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (Williston Park). 2002;16:1024–38, 42; discussion 42, 47–8, 51.
   Google Scholar
• Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431–440.
   PubMed Web of Science ®Google Scholar
• Berger VW. Does the Prentice criterion validate surrogate endpoints? Stat Med. 2004;23:1571–1578.
   PubMed Web of Science ®Google Scholar
• Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605–613.
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Lisboa R, Weinreb RN, et al. Retinal ganglion cell count estimates associated with early development of visual field defects in glaucoma. Ophthalmology. 2013;120:736–744.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Kaufman PL. Glaucoma research community and FDA look to the future, II: NEI/FDA glaucoma clinical trial design and endpoints symposium: measures of structural change and visual function. Invest Ophthalmol Vis Sci. 2011;52:7842–7851.
   PubMed Web of Science ®Google Scholar
• Lotery A. New ideas for glaucoma. Eye. 2015;29:1241.
   PubMed Web of Science ®Google Scholar
• Sullivan-Mee M, Gerhardt G, Halverson KD, et al. Repeatability and reproducibility for intraocular pressure measurement by dynamic contour, ocular response analyzer, and Goldmann applanation tonometry. J Glaucoma. 2009;18:666–673.
   PubMed Web of Science ®Google Scholar
• Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–142.
   PubMed Web of Science ®Google Scholar
• Shah S, Chatterjee A, Mathai M, et al. Relationship between corneal thickness and measured intraocular pressure in a general ophthalmology clinic. Ophthalmology. 1999;106:2154–2160.
   PubMed Web of Science ®Google Scholar
• David R, Zangwill L, Briscoe D, et al. Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. Br J Ophthalmol. 1992;76:280–283.
   PubMed Web of Science ®Google Scholar
• Sehi M, Flanagan JG, Zeng L, et al. Relative change in diurnal mean ocular perfusion pressure: a risk factor for the diagnosis of primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2005;46:561–567.
   PubMed Web of Science ®Google Scholar
• Gautam N, Kaur S, Kaushik S, et al. Postural and diurnal fluctuations in intraocular pressure across the spectrum of glaucoma. Br J Ophthalmol. 2016;100:537–541.
   PubMed Web of Science ®Google Scholar
• Moses RA, Carniglia PE, Grodzki WJ, et al. Proptosis and increase of intraocular pressure in voluntary lid fissure widening. Invest Ophthalmol Vis Sci. 1984;25:989–992.
   PubMed Web of Science ®Google Scholar
• Jamal KN, Gürses-Ozden R, Liebmann JM, et al. Attempted eyelid closure affects intraocular pressure measurement in open-angle glaucoma patients. Am J Ophthalmol. 2002;134:186–189.
   PubMed Web of Science ®Google Scholar
• Rafuse PE, Mills DW, Hooper PL, et al. Effects of Valsalva’s manoeuvre on intraocular pressure. Can J Ophthalmol. 1994;29:73–76.
   PubMed Web of Science ®Google Scholar
• Lundmark PO, Trope GE, Flanagan JG. The effect of simulated obstructive apnoea on intraocular pressure and pulsatile ocular blood flow in healthy young adults. Br J Ophthalmol. 2003;87:1363–1369.
   PubMed Web of Science ®Google Scholar
• Vieira GM, Oliveira HB, de Andrade DT, et al. Intraocular pressure variation during weight lifting. Arch Ophthalmol. 2006;124:1251–1254.
   PubMedGoogle Scholar
• Lempert P, Cooper KH, Culver JF, et al. The effect of exercise on intraocular pressure. Am J Ophthalmol. 1967;63:1673–1676.
   PubMed Web of Science ®Google Scholar
• McDaniel DR, Tribbey CL, Tobias GS. Effects of moderate exercise on intraocular pressure. Am J Optom Physiol Opt. 1983;60:154–157.
   PubMedGoogle Scholar
• Qureshi IA. Effects of mild, moderate and severe exercise on intraocular pressure of sedentary subjects. Ann Hum Biol. 1995;22:545–553.
   PubMed Web of Science ®Google Scholar
• Tarkkanen A, Leikola J. Postural variations of the intraocular pressure as measured with the Mackay-Marg tonometer. Acta Ophthalmol (Copenh). 1967;45:569–575.
   PubMed Web of Science ®Google Scholar
• Song YK, Lee C-K, Kim J, et al. Instability of 24-hour intraocular pressure fluctuation in healthy young subjects: a prospective, cross-sectional study. BMC Ophthalmol. 2014;14:127.
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268–1279.
   PubMed Web of Science ®Google Scholar
• Investigators A. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS investigators. Am J Ophthalmol. 2000;130:429–440.
   PubMed Web of Science ®Google Scholar
• Drance SM. The collaborative normal-tension glaucoma study and some of its lessons. Can J Ophthalmol. 1999;34:1–6.
   PubMed Web of Science ®Google Scholar
• Tomita G. The optic nerve head in normal-tension glaucoma. Curr Opin Ophthalmol. 2000;11:116–120.
   PubMedGoogle Scholar
• Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011;151:671–681.
   PubMed Web of Science ®Google Scholar
• Cordeiro MF, Levin LA. Clinical evidence for neuroprotection in glaucoma. Am J Ophthalmol. 2011;152:715–716.
   PubMed Web of Science ®Google Scholar
• Bengtsson B, Leske MC, Hyman L, et al. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:205–209.
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Weinreb RN, Zangwill LM, et al. Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology. 2008;115:934–940.
   PubMed Web of Science ®Google Scholar
• Downs JC. IOP telemetry in the nonhuman primate. Exp Eye Res. 2015;141:91–98.
   PubMed Web of Science ®Google Scholar
• Fogagnolo P, Figus M, Frezzotti P, et al. Test-retest variability of intraocular pressure and ocular pulse amplitude for dynamic contour tonometry: a multicentre study. Br J Ophthalmol. 2010;94:419–423.
   PubMed Web of Science ®Google Scholar
• Punjabi OS, Ho HK, Kniestedt C, et al. Intraocular pressure and ocular pulse amplitude comparisons in different types of glaucoma using dynamic contour tonometry. Curr Eye Res. 2006;31:851–862.
   PubMed Web of Science ®Google Scholar
• Pourjavan S, Boelle PY, Detry-Morel M, et al. Physiological diurnal variability and characteristics of the ocular pulse amplitude (OPA) with the dynamic contour tonometer (DCT-Pascal). Int Ophthalmol. 2007;27:357–360.
   PubMedGoogle Scholar
• Mansouri K, Shaarawy T. Continuous intraocular pressure monitoring with a wireless ocular telemetry sensor: initial clinical experience in patients with open angle glaucoma. Br J Ophthalmol. 2011;95:627–629.
   PubMed Web of Science ®Google Scholar
• Koutsonas A, Walter P, Roessler G, et al. Implantation of a novel telemetric intraocular pressure sensor in patients with glaucoma (ARGOS study): 1-year results. Invest Ophthalmol Vis Sci. 2015;56:1063–1069.
   PubMed Web of Science ®Google Scholar
• Downs JC, Burgoyne CF, Seigfreid WP, et al. 24-hour IOP telemetry in the nonhuman primate: implant system performance and initial characterization of IOP at multiple timescales. Invest Ophthalmol Vis Sci. 2011;52:7365–7375.
   PubMed Web of Science ®Google Scholar
• Gardiner SK, Fortune B, Wang L, et al. Intraocular pressure magnitude and variability as predictors of rates of structural change in non-human primate experimental glaucoma. Exp Eye Res. 2012;103:1–8.
   PubMed Web of Science ®Google Scholar
• Turner DC, Samuels BC, Huisingh C, et al. The magnitude and time course of IOP change in response to body position change in nonhuman primates measured using continuous IOP telemetry. Invest Ophthalmol Vis Sci. 2017;58:6232–6240.
   PubMed Web of Science ®Google Scholar
• Zeyen TG, Caprioli J. Progression of disc and field damage in early glaucoma. Arch Ophthalmol. 1993;111:62–65.
   PubMed Web of Science ®Google Scholar
• Alasil T, Wang K, Yu F, et al. Correlation of retinal nerve fiber layer thickness and visual fields in glaucoma: a broken stick model. Am J Ophthalmol. 2014;157:953–959.
   PubMed Web of Science ®Google Scholar
• Quigley HA, Green WR. The histology of human glaucoma cupping and optic nerve damage: clinicopathologic correlation in 21 eyes. Ophthalmology. 1979;86:1803–1830.
   PubMed Web of Science ®Google Scholar
• Kuang TM, Zhang C, Zangwill LM, et al. Estimating lead time gained by optical coherence tomography in detecting glaucoma before development of visual field defects. Ophthalmology. 2015;122:2002–2009.
   PubMed Web of Science ®Google Scholar
• Yu M, Lin C, Weinreb RN, et al. Risk of visual field progression in glaucoma patients with progressive retinal nerve fiber layer thinning: a 5-year prospective study. Ophthalmology. 2016;123:1201–1210.
   PubMed Web of Science ®Google Scholar
• Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol. 1982;100:135–146.
   PubMed Web of Science ®Google Scholar
• Blumenthal EZ, Horani A, Sasikumar R, et al. Correlating structure with function in end-stage glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37:218–223.
   PubMedGoogle Scholar
• Anderson DR, Hendrickson A. Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve. Invest Ophthalmol. 1974;13:771–783.
   PubMedGoogle Scholar
• Quigley HA, Guy J, Anderson DR. Blockade of rapid axonal transport. Effect of intraocular pressure elevation in primate optic nerve. Arch Ophthalmol. 1979;97:525–531.
   PubMedGoogle Scholar
• Downs JC, Girkin CA. Lamina cribrosa in glaucoma. Curr Opin Ophthalmol. 2017;28:113–119.
   PubMed Web of Science ®Google Scholar
• Jonas JB, Schmidt AM, Müller-Bergh JA, et al. Human optic nerve fiber count and optic disc size. Invest Ophthalmol Vis Sci. 1992;33:2012–2018.
   PubMed Web of Science ®Google Scholar
• Teitelbaum BA, Haefs R, Connor D. Interobserver variability in the estimation of the cup/disk ratio among observers of differing educational background. Optometry. 2001;72:729–732.
   PubMedGoogle Scholar
• Azuara-Blanco A, Katz LJ, Spaeth GL, et al. Clinical agreement among glaucoma experts in the detection of glaucomatous changes of the optic disk using simultaneous stereoscopic photographs. Am J Ophthalmol. 2003;136:949–950.
   PubMed Web of Science ®Google Scholar
• Chauhan BC, LeBlanc RP, McCormick TA, et al. Test-retest variability of topographic measurements with confocal scanning laser tomography in patients with glaucoma and control subjects. Am J Ophthalmol. 1994;118:9–15.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Shakiba S, Zangwill L. Scanning laser polarimetry to measure the nerve fiber layer of normal and glaucomatous eyes. Am J Ophthalmol. 1995;119:627–636.
   PubMed Web of Science ®Google Scholar
• Schuman JS. Spectral domain optical coherence tomography for glaucoma (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:426–458.
   PubMedGoogle Scholar
• Chang RT, Knight ORJ, Feuer WJ, et al. Sensitivity and specificity of time-domain versus spectral-domain optical coherence tomography in diagnosing early to moderate glaucoma. Ophthalmology. 2009;116:2294–2299.
   PubMed Web of Science ®Google Scholar
• DeLeón Ortega JE, Sakata LM, Kakati B, et al. Effect of glaucomatous damage on repeatability of confocal scanning laser ophthalmoscope, scanning laser polarimetry, and optical coherence tomography. Invest Ophthalmol Vis Sci. 2007;48:1156–1163.
   PubMed Web of Science ®Google Scholar
• Tan BB, Natividad M, Chua K-C, et al. Comparison of retinal nerve fiber layer measurement between 2 spectral domain OCT instruments. J Glaucoma. 2012;21:266–273.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kim JM, Park KH, et al. Effect of media opacity on retinal nerve fiber layer thickness measurements by optical coherence tomography. J Ophthalmic Vis Res. 2010;5:151–157.
   PubMedGoogle Scholar
• Hwang YH, Kim YY. Effect of peripapillary vitreous opacity on retinal nerve fiber layer thickness measurement using optical coherence tomography. Arch Ophthalmol. 2012;130:789–792.
   PubMedGoogle Scholar
• Gmeiner JM, Schrems WA, Mardin CY, et al. Comparison of Bruch’s membrane opening minimum rim width and peripapillary retinal nerve fiber layer thickness in early glaucoma assessment. Invest Ophthalmol Vis Sci. 2016;57:OCT575–84.
   PubMed Web of Science ®Google Scholar
• cZhang X, Loewen N, Tan O, et al. Predicting development of glaucomatous visual field conversion using baseline Fourier-domain optical coherence tomography. Am J Ophthalmol. 2016;163:29–37.
   PubMed Web of Science ®Google Scholar
• Zhang X, Dastiridou A, Francis BA, et al. Baseline Fourier-domain optical coherence tomography structural risk factors for visual field progression in the advanced imaging for glaucoma Study. Am J Ophthalmol. 2016;172:94–103.
   PubMed Web of Science ®Google Scholar
• Realini T, Zangwill LM, Flanagan JG, et al. Normative databases for imaging instrumentation. J Glaucoma. 2015;24:480–483.
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Alencar LM, Zangwill LM, et al. Prediction of functional loss in glaucoma from progressive optic disc damage. Arch Ophthalmol. 2009;127:1250–1256.
   PubMed Web of Science ®Google Scholar
• Chauhan BC, Nicolela MT, Artes PH. Incidence and rates of visual field progression after longitudinally measured optic disc change in glaucoma. Ophthalmology. 2009;116:2110–2118.
   PubMed Web of Science ®Google Scholar
• Meira-Freitas D, Lisboa R, Tatham A, et al. Predicting progression in glaucoma suspects with longitudinal estimates of retinal ganglion cell counts. Invest Ophthalmol Vis Sci. 2013;54:4174–4183.
   PubMed Web of Science ®Google Scholar
• Miki A, Medeiros FA, Weinreb RN, et al. Rates of retinal nerve fiber layer thinning in glaucoma suspect eyes. Ophthalmology. 2014;121:1350–1358.
   PubMed Web of Science ®Google Scholar
• Lin C, Mak H, Yu M, et al. Trend-based progression analysis for examination of the topography of rates of retinal nerve fiber layer thinning in glaucoma. JAMA Ophthalmol. 2017;135:189–195.
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Lisboa R, Zangwill LM, et al. Evaluation of progressive neuroretinal rim loss as a surrogate end point for development of visual field loss in glaucoma. Ophthalmology. 2014;121:100–109.
   PubMed Web of Science ®Google Scholar
• Mansouri K, Nuyen B, N Weinreb R. Improved visualization of deep ocular structures in glaucoma using high penetration optical coherence tomography. Expert Rev Med Devices. 2013;10:621–628.
   PubMed Web of Science ®Google Scholar
• Yang Z, Tatham AJ, Zangwill LM, et al. Diagnostic ability of retinal nerve fiber layer imaging by swept-source optical coherence tomography in glaucoma. Am J Ophthalmol. 2015;159:193–201.
   PubMed Web of Science ®Google Scholar
• Furlanetto RL, Park SC, Damle UJ, et al. Posterior displacement of the lamina cribrosa in glaucoma: in vivo interindividual and intereye comparisons. Invest Ophthalmol Vis Sci. 2013;54:4836–4842.
   PubMed Web of Science ®Google Scholar
• Park SC, Brumm J, Furlanetto RL, et al. Lamina cribrosa depth in different stages of glaucoma. Invest Ophthalmol Vis Sci. 2015;56:2059–2064.
   PubMed Web of Science ®Google Scholar
• Lee KM, Kim T-W, Weinreb RN, et al. Anterior lamina cribrosa insertion in primary open-angle glaucoma patients and healthy subjects. PLoS One. 2014;9:e114935.
   PubMed Web of Science ®Google Scholar
• Tun TA, Thakku SG, Png O, et al. Shape changes of the anterior lamina cribrosa in normal, ocular hypertensive, and glaucomatous eyes following acute intraocular pressure elevation. Invest Ophthalmol Vis Sci. 2016;57:4869–4877.
   PubMed Web of Science ®Google Scholar
• Omodaka K, Takahashi S, Matsumoto A, et al. Clinical factors associated with lamina cribrosa thickness in patients with glaucoma, as measured with swept source optical coherence tomography. PLoS One. 2016;11:e0153707.
   PubMed Web of Science ®Google Scholar
• Takayama K, Hangai M, Kimura Y, et al. Three-dimensional imaging of lamina cribrosa defects in glaucoma using swept-source optical coherence tomography. Invest Ophthalmol Vis Sci. 2013;54:4798–4807.
   PubMed Web of Science ®Google Scholar
• You JY, Park SC, Su D, et al. Focal lamina cribrosa defects associated with glaucomatous rim thinning and acquired pits. JAMA Ophthalmol. 2013;131:314–320.
   PubMed Web of Science ®Google Scholar
• Li L, Bian A, Cheng G, et al. Posterior displacement of the lamina cribrosa in normal-tension and high-tension glaucoma. Acta Ophthalmol. 2016;94:e492–500.
   PubMed Web of Science ®Google Scholar
• Wu Z, Lin C, Crowther M, et al. Impact of rates of change of lamina cribrosa and optic nerve head surface depths on visual field progression in glaucoma. Invest Ophthalmol Vis Sci. 2017;58:1825–1833.
   PubMed Web of Science ®Google Scholar
• Wu Z, Xu G, Weinreb RN, et al. Optic nerve head deformation in glaucoma: a prospective analysis of optic nerve head surface and lamina cribrosa surface displacement. Ophthalmology. 2015;122:1317–1329.
   PubMed Web of Science ®Google Scholar
• Zhang C, Tatham AJ, Medeiros FA, et al. Assessment of choroidal thickness in healthy and glaucomatous eyes using swept source optical coherence tomography. PLoS One. 2014;9:e109683.
   PubMed Web of Science ®Google Scholar
• Song YJ, Kim YK, Jeoung JW, et al. Assessment of open-angle glaucoma peripapillary and macular choroidal thickness using swept-source optical coherence tomography (SS-OCT). PLoS One. 2016;11:e0157333.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang X. Choroidal thickness and primary open-angle glaucoma: a cross-sectional study and meta-analysis. Invest Ophthalmol Vis Sci. 2014;55:6007–6014.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yu M, Wang F, et al. Choroidal thickness and open-angle glaucoma: a meta-analysis and systematic review. J Glaucoma. 2016;25:e446–54.
   PubMed Web of Science ®Google Scholar
• Jia Y, Wei E, Wang X, et al. Optical coherence tomography angiography of optic disc perfusion in glaucoma. Ophthalmology. 2014;121:1322–1332.
   PubMed Web of Science ®Google Scholar
• Holló G. Intrasession and between-visit variability of sector peripapillary angioflow vessel density values measured with the angiovue optical coherence tomograph in different retinal layers in ocular hypertension and glaucoma. PLoS One. 2016;11:e0161631.
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang C, Ko T, et al. Correlation between optic disc perfusion and glaucomatous severity in patients with open-angle glaucoma: an optical coherence tomography angiography study. Graefes Arch Clin Exp Ophthalmol. 2015;253:1557–1564.
   PubMed Web of Science ®Google Scholar
• Liu L, Jia Y, Takusagawa HL, et al. Optical coherence tomography angiography of the peripapillary retina in glaucoma. JAMA Ophthalmol. 2015;133:1045–1052.
   PubMed Web of Science ®Google Scholar
• Holló G. Relationship between OCT angiography temporal peripapillary vessel-density and octopus perimeter paracentral cluster mean defect. J Glaucoma. 2017;26:397–402.
   PubMed Web of Science ®Google Scholar
• Holló G. Influence of large intraocular pressure reduction on peripapillary OCT vessel density in ocular hypertensive and glaucoma eyes. J Glaucoma. 2017;26:e7–e10.
   PubMed Web of Science ®Google Scholar
• Cherecheanu AP, Garhofer G, Schmidl D, et al. Ocular perfusion pressure and ocular blood flow in glaucoma. Curr Opin Pharmacol. 2013;13:36–42.
   PubMed Web of Science ®Google Scholar
• Fan N, Wang P, Tang L, et al. Ocular blood flow and normal tension glaucoma. Biomed Res Int. 2015;2015:308505.
   PubMedGoogle Scholar
• Liang J, Williams DR, Miller DT. Supernormal vision and high-resolution retinal imaging through adaptive optics. J Opt Soc Am A Opt Image Sci Vis. 1997;14:2884–2892.
   PubMed Web of Science ®Google Scholar
• Dong ZM, Wollstein G, Wang B, et al. Adaptive optics optical coherence tomography in glaucoma. Prog Retin Eye Res. 2017;57:76–88.
   PubMed Web of Science ®Google Scholar
• Kocaoglu OP, Turner TL, Liu Z, et al. Adaptive optics optical coherence tomography at 1 MHz. Biomed Opt Express. 2014;5:4186–4200.
   PubMedGoogle Scholar
• Kocaoglu OP, Cense B, Jonnal RS, et al. Imaging retinal nerve fiber bundles using optical coherence tomography with adaptive optics. Vision Res. 2011;51:1835–1844.
   PubMed Web of Science ®Google Scholar
• Huang XR, Zhou Y, Kong W, et al. Reflectance decreases before thickness changes in the retinal nerve fiber layer in glaucomatous retinas. Invest Ophthalmol Vis Sci. 2011;52:6737–6742.
   PubMed Web of Science ®Google Scholar
• Sigal IA, Wang B, Strouthidis NG, et al. Recent advances in OCT imaging of the lamina cribrosa. Br J Ophthalmol. 2014;98(Suppl 2):ii34–9.
   PubMedGoogle Scholar
• Jian Y, Lee S, Ju MJ, et al. Lens-based wavefront sensorless adaptive optics swept source OCT. Sci Rep. 2016;6:27620.
   PubMed Web of Science ®Google Scholar
• Bengtsson B, Heijl A, Olsson J. Evaluation of a new threshold visual field strategy, SITA, in normal subjects. Swedish interactive thresholding algorithm. Acta Ophthalmol Scand. 1998;76:165–169.
   PubMedGoogle Scholar
• Pierre-Filho Pde T, Gomes PR, Pierre ET, et al. Learning effect in visual field testing of healthy subjects using Humphrey matrix frequency doubling technology perimetry. Eye (Lond). 2010;24:851–856.
   PubMed Web of Science ®Google Scholar
• Gardiner SK, Demirel S, Johnson CA. Is there evidence for continued learning over multiple years in perimetry? Optom Vis Sci. 2008;85:1043–1048.
   PubMed Web of Science ®Google Scholar
• Ophir A. First-visit diagnosis of preperimetric glaucoma. Open Ophthalmol J. 2010;4:22–27.
   PubMedGoogle Scholar
• Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol. 1989;107:453–464.
   PubMed Web of Science ®Google Scholar
• Heijl A, Buchholz P, Norrgren G, et al. Rates of visual field progression in clinical glaucoma care. Acta Ophthalmol. 2013;91:406–412.
   PubMed Web of Science ®Google Scholar
• Chauhan BC, Garway-Heath DF, Goñi FJ, et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol. 2008;92:569–573.
   PubMed Web of Science ®Google Scholar
• Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295–1304.
   PubMed Web of Science ®Google Scholar
• Anderson DR. Normal tension glaucoma study. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003;14:86–90.
   PubMedGoogle Scholar
• Musch DC, Gillespie BW, Niziol LM, et al. Intraocular pressure control and long-term visual field loss in the collaborative initial glaucoma treatment study. Ophthalmology. 2011;118:1766–1773.
   PubMed Web of Science ®Google Scholar
• Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The latanoprost study group. Ophthalmology. 1996;103:126–137.
   PubMed Web of Science ®Google Scholar
• Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States latanoprost study group. Ophthalmology. 1996;103:138–147.
   PubMed Web of Science ®Google Scholar
• Camras CB, Alm A, Watson P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost study groups. Ophthalmology. 1996;103:1916–1924.
   PubMed Web of Science ®Google Scholar
• Bengtsson B, Patella VM, Heijl A. Prediction of glaucomatous visual field loss by extrapolation of linear trends. Arch Ophthalmol. 2009;127:1610–1615.
   PubMedGoogle Scholar
• Bengtsson B, Heijl A. A visual field index for calculation of glaucoma rate of progression. Am J Ophthalmol. 2008;145:343–353.
   PubMed Web of Science ®Google Scholar
• Vesti E, Johnson CA, Chauhan BC. Comparison of different methods for detecting glaucomatous visual field progression. Invest Ophthalmol Vis Sci. 2003;44:3873–3879.
   PubMed Web of Science ®Google Scholar
• Williams TA, Roberts MA, Austin MW. Comparison of clinical interpretation versus Progressor® software in visual field analysis in glaucoma follow up. Invest Ophthalmol Vis Sci. 2010;51:4001.
   Google Scholar
• O’Leary N, Chauhan BC, Artes PH. Visual field progression in glaucoma: estimating the overall significance of deterioration with permutation analyses of pointwise linear regression (PoPLR). Invest Ophthalmol Vis Sci. 2012;53:6776–6784.
   PubMed Web of Science ®Google Scholar
• Karakawa A, Murata H, Hirasawa H, et al. Detection of progression of glaucomatous visual field damage using the point-wise method with the binomial test. PLoS One. 2013;8:e78630.
   PubMed Web of Science ®Google Scholar
• Zhu H, Crabb DP, Ho T, et al. More accurate modeling of visual field progression in glaucoma: ANSWERS. Invest Ophthalmol Vis Sci. 2015;56:6077–6083.
   PubMed Web of Science ®Google Scholar
• Artes PH, O’Leary N, Nicolela MT, et al. Visual field progression in glaucoma: what is the specificity of the guided progression analysis? Ophthalmology. 2014;121:2023–2027.
   PubMed Web of Science ®Google Scholar
• Casas-Llera P, Rebolleda G, Munoz-Negrete FJ, et al. Visual field index rate and event-based glaucoma progression analysis: comparison in a glaucoma population. Br J Ophthalmol. 2009;93:1576–1579.
   PubMed Web of Science ®Google Scholar
• Chauhan BC, Henson DB, Hobley AJ. Cluster analysis in visual field quantification. Doc Ophthalmol. 1988;69:25–39.
   PubMed Web of Science ®Google Scholar
• Naghizadeh F, Hollo G. Detection of early glaucomatous progression with octopus cluster trend analysis. J Glaucoma. 2014;23:269–275.
   PubMed Web of Science ®Google Scholar
• Mandava S, Zulauf M, Zeyen T, et al. An evaluation of clusters in the glaucomatous visual field. Am J Ophthalmol. 1993;116:684–691.
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K, Brigatti L, Weitzman M, et al. Comparison of methods to detect visual field progression in glaucoma. Ophthalmology. 1997;104:1228–1236.
   PubMed Web of Science ®Google Scholar
• Bono V, Normando EM, Davis B, et al. Cluster visual field progression and its relationship with optic disc changes. Invest Ophthalmol Vis Sci. 2015;56:1044.
   Web of Science ®Google Scholar
• Abe RY, Diniz-Filho A, Costa VP, et al. The impact of location of progressive visual field loss on longitudinal changes in quality of life of patients with glaucoma. Ophthalmology. 2016;123:552–557.
   PubMed Web of Science ®Google Scholar
• Drance SM. The early field defects in glaucoma. Invest Ophthalmol. 1969;8:84–91.
   PubMedGoogle Scholar
• Schiefer U, Papageorgiou E, Sample PA, et al. Spatial pattern of glaucomatous visual field loss obtained with regionally condensed stimulus arrangements. Invest Ophthalmol Vis Sci. 2010;51:5685–5689.
   PubMed Web of Science ®Google Scholar
• Traynis I, De Moraes CG, Raza AS, et al. Prevalence and nature of early glaucomatous defects in the central 10 degrees of the visual field. JAMA Ophthalmol. 2014;132:291–297.
   PubMed Web of Science ®Google Scholar
• Curcio CA, Allen KA. Topography of ganglion cells in human retina. J Comp Neurol. 1990;300:5–25.
   PubMed Web of Science ®Google Scholar
• De Moraes CG, Hood DC, Thenappan A, et al. 24-2 visual fields miss central defects shown on 10-2 tests in glaucoma suspects, ocular hypertensives, and early glaucoma. Ophthalmology. 2017;124:1449–1456.
   PubMed Web of Science ®Google Scholar
• Park SC, Kung Y, Su D, et al. Parafoveal scotoma progression in glaucoma: Humphrey 10-2 versus 24-2 visual field analysis. Ophthalmology. 2013;120:1546–1550.
   PubMed Web of Science ®Google Scholar
• de Moraes CG, Song C, Liebmann JM, et al. Defining 10-2 visual field progression criteria: exploratory and confirmatory factor analysis using pointwise linear regression. Ophthalmology. 2014;121:741–749.
   PubMed Web of Science ®Google Scholar
• Weber J, Schultze T, Ulrich H. The visual field in advanced glaucoma. Int Ophthalmol. 1989;13:47–50.
   PubMed Web of Science ®Google Scholar
• Rao HL, Begum VU, Khadka D, et al. Comparing glaucoma progression on 24-2 and 10-2 visual field examinations. PLoS One. 2015;10:e0127233.
   PubMed Web of Science ®Google Scholar
• Anderson AJ, Johnson CA. Frequency-doubling technology perimetry. Ophthalmol Clin North Am. 2003;16:213–225.
   PubMedGoogle Scholar
• Maddess T, Hemmi JM, James AC. Evidence for spatial aliasing effects in the Y-like cells of the magnocellular visual pathway. Vision Res. 1998;38:1843–1859.
   PubMed Web of Science ®Google Scholar
• White AJR, Sun H, Swanson WH, et al. An examination of physiological mechanisms underlying the frequency-doubling illusion. Invest Ophthalmol Vis Sci. 2002;43:3590–3599.
   PubMed Web of Science ®Google Scholar
• Zeppieri M, Demirel S, Kent K, et al. Perceived spatial frequency of sinusoidal gratings. Optom Vis Sci. 2008;85:318–329.
   PubMed Web of Science ®Google Scholar
• Chauhan BC, Johnson CA. Test-retest variability of frequency-doubling perimetry and conventional perimetry in glaucoma patients and normal subjects. Invest Ophthalmol Vis Sci. 1999;40:648–656.
   PubMed Web of Science ®Google Scholar
• Spry PG, Johnson CA, McKendrick AM, et al. Variability components of standard automated perimetry and frequency-doubling technology perimetry. Invest Ophthalmol Vis Sci. 2001;42:1404–1410.
   PubMed Web of Science ®Google Scholar
• Pierre-Filho Pde T, Schimiti RB, de Vasconcellos JP, et al. Sensitivity and specificity of frequency-doubling technology, tendency-oriented perimetry, SITA standard and SITA fast perimetry in perimetrically inexperienced individuals. Acta Ophthalmol Scand. 2006;84:345–350.
   PubMedGoogle Scholar
• Artes PH, Hutchison DM, Nicolela MT, et al. Threshold and variability properties of matrix frequency-doubling technology and standard automated perimetry in glaucoma. Invest Ophthalmol Vis Sci. 2005;46:2451–2457.
   PubMed Web of Science ®Google Scholar
• Leeprechanon N, Giangiacomo A, Fontana H, et al. Frequency-doubling perimetry: comparison with standard automated perimetry to detect glaucoma. Am J Ophthalmol. 2007;143:263–271.
   PubMed Web of Science ®Google Scholar
• Johnson CA, Cioffi GA, Van Buskirk EM. Frequency doubling technology perimetry using a 24–2 stimulus presentation pattern. Optom Vis Sci. 1999;76:571–581.
   PubMed Web of Science ®Google Scholar
• Liu S, Lam S, Weinreb RN, et al. Comparison of standard automated perimetry, frequency-doubling technology perimetry, and short-wavelength automated perimetry for detection of glaucoma. Invest Ophthalmol Vis Sci. 2011;52:7325–7331.
   PubMed Web of Science ®Google Scholar
• Hu R, Wang C, Racette L. Comparison of matrix frequency-doubling technology perimetry and standard automated perimetry in monitoring the development of visual field defects for glaucoma suspect eyes. PLoS One. 2017;12:e0178079.
   PubMed Web of Science ®Google Scholar
• Hu R, Wang C, Gu Y, et al. Comparison of standard automated perimetry, short-wavelength automated perimetry, and frequency-doubling technology perimetry to monitor glaucoma progression. Medicine (Baltimore). 2016;95:e2618.
   PubMed Web of Science ®Google Scholar
• Rossetti L, Digiuni M, Rosso A, et al. Compass: clinical evaluation of a new instrument for the diagnosis of glaucoma. PLoS One. 2015;10:e0122157.
   PubMed Web of Science ®Google Scholar
• Hirooka K, Misaki K, Nitta E, et al. Comparison of macular integrity assessment (MAIA), MP-3, and the Humphrey field analyzer in the evaluation of the relationship between the structure and function of the macula. PLoS One. 2016;11:e0151000.
   PubMed Web of Science ®Google Scholar
• Lima VC, Prata TS, De Moraes CG, et al. A comparison between microperimetry and standard achromatic perimetry of the central visual field in eyes with glaucomatous paracentral visual-field defects. Br J Ophthalmol. 2010;94:64–67.
   PubMed Web of Science ®Google Scholar
• Ratra V, Ratra D, Gupta M, et al. Comparison between Humphrey field analyzer and micro perimeter 1 in normal and glaucoma subjects. Oman J Ophthalmol. 2012;5:97–102.
   PubMedGoogle Scholar
• Aslam TM, Murray IJ, Lai MY, et al. An assessment of a modern touch-screen tablet computer with reference to core physical characteristics necessary for clinical vision testing. J R Soc Interface. 2013;10:20130239.
   PubMed Web of Science ®Google Scholar
• Tahir HJ, Murray IJ, Parry NR, et al. Optimisation and assessment of three modern touch screen tablet computers for clinical vision testing. PLoS One. 2014;9:e95074.
   PubMed Web of Science ®Google Scholar
• Kong YXG, He M, Crowston JG, et al. A comparison of perimetric results from a tablet perimeter and Humphrey field analyzer in glaucoma patients. Transl Vis Sci Technol. 2016;5:2.
   PubMed Web of Science ®Google Scholar
• Johnson CA, Thapa S, George Kong YX, et al. Performance of an iPad application to detect moderate and advanced visual field loss in Nepal. Am J Ophthalmol. 2017;182:147–154.
   PubMed Web of Science ®Google Scholar
• Anderson AJ, Bedggood PA, Kong YXG, et al. Can home monitoring allow earlier detection of rapid visual field progression in glaucoma? Ophthalmology. 2017; 0.
   Google Scholar
• Danesh-Meyer HV, Levin LA. Glaucoma as a neurodegenerative disease. J Neuroophthalmol. 2015;35(Suppl 1):S22–8.
   PubMedGoogle Scholar
• Gauthier AC, Liu J. Neurodegeneration and neuroprotection in glaucoma. Yale J Biol Med. 2016;89:73–79.
   PubMedGoogle Scholar
• Garcia-Valenzuela E, Shareef S, Walsh J, et al. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res. 1995;61:33–44.
   PubMed Web of Science ®Google Scholar
• Quigley HA, Nickells RW, Kerrigan LA, et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774–786.
   PubMed Web of Science ®Google Scholar
• Qu J, Wang D, Grosskreutz CL. Mechanisms of retinal ganglion cell injury and defense in glaucoma. Exp Eye Res. 2010;91:48–53.
   PubMed Web of Science ®Google Scholar
• Yücel YH, Zhang Q, Weinreb RN, et al. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retin Eye Res. 2003;22:465–481.
   PubMed Web of Science ®Google Scholar
• Gupta N, Ang L-C, Noël de Tilly L, et al. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br J Ophthalmol. 2006;90:674–678.
   PubMed Web of Science ®Google Scholar
• Cordeiro MF. DARC: a new method for detecting progressive neuronal death. Eye. 2007;21:S15-S17.
   Web of Science ®Google Scholar
• Cordeiro MF, Normando EM, Cardoso MJ, et al. Real-time imaging of single neuronal cell apoptosis in patients with glaucoma. Brain. 2017;140:1757–1767.
   PubMed Web of Science ®Google Scholar
• Thimister PWL, Hofstra L, Liem IH, et al. In vivo detection of cell death in the area at risk in acute myocardial infarction. J Nucl Med. 2003;44:391–396.
   PubMed Web of Science ®Google Scholar
• Lampl Y, Lorberboym M, Blankenberg FG, et al. Annexin V SPECT imaging of phosphatidylserine expression in patients with dementia. Neurology. 2006;66:1253–1254.
   PubMed Web of Science ®Google Scholar
• Hoebers FJP, Kartachova M, de Bois J, et al. 99mTc Hynic-rh-annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2008;35:509–518.
   PubMed Web of Science ®Google Scholar
• Cordeiro MF, Guo L, Luong V et al. Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc Natl Acad Sci U S A. 2004;101:13352–13356.
   PubMed Web of Science ®Google Scholar
• Davis BM, Tian K, Pahlitzsch M, et al. Topical coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension. Mitochondrion. 2017;36:114–123.
   PubMed Web of Science ®Google Scholar
• Normando EM, Davis BM, De Groef L, et al. The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain. Acta Neuropathol Commun. 2016;4:86.
   PubMed Web of Science ®Google Scholar
• Wolfs RC, Klaver CC, Ramrattan RS, et al. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch Ophthalmol. 1998;116:1640–1645.
   PubMed Web of Science ®Google Scholar
• Wang X, Harmon J, Zabrieskie N, et al. Using the Utah population database to assess familial risk of primary open angle glaucoma. Vision Res. 2010;50:2391–2395.
   PubMed Web of Science ®Google Scholar
• Nakano M, Ikeda Y, Taniguchi T, et al. Three susceptible loci associated with primary open-angle glaucoma identified by genome-wide association study in a Japanese population. Proc Natl Acad Sci U S A. 2009;106:12838–12842.
   PubMed Web of Science ®Google Scholar
• Burdon KP, Macgregor S, Hewitt AW, et al. Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nat Genet. 2011;43:574–578.
   PubMed Web of Science ®Google Scholar
• Wiggs JL, Pasquale LR. Genetics of glaucoma. Hum Mol Genet. 2017;26:R21–R7.
   PubMed Web of Science ®Google Scholar
• Liu Y, Allingham RR. Major review: molecular genetics of primary open-angle glaucoma. Exp Eye Res. 2017;160:62–84.
   PubMed Web of Science ®Google Scholar
• Bailey JNC, Loomis SJ, Kang JH, et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet. 2016;48:189–194.
   PubMed Web of Science ®Google Scholar
• Fan BJ, Wang DY, Lam DSC, et al. Gene mapping for primary open angle glaucoma. Clin Biochem. 2006;39:249–258.
   PubMed Web of Science ®Google Scholar
• Pulst SM, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet. 1996;14:269–276.
   PubMed Web of Science ®Google Scholar
• Elden AC, Kim H-J, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069–1075.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Lichter PR, Johnson AT, et al. Age-dependent prevalence of mutations at the GLC1A locus in primary open-angle glaucoma. Am J Ophthalmol. 2000;130:165–177.
   PubMed Web of Science ®Google Scholar
• Waryah AM, Narsani AK, Sheikh SA, et al. The novel heterozygous Thr377Arg MYOC mutation causes severe juvenile open angle glaucoma in a large Pakistani family. Gene. 2013;528:356–359.
   PubMed Web of Science ®Google Scholar
• Gupta V, Somarajan BI, Gupta S, et al. The inheritance of juvenile onset primary open angle glaucoma. Clin Genet. 2017;92:134–142.
   PubMed Web of Science ®Google Scholar
• Fingert JH, Héon E, Liebmann JM, et al. Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Hum Mol Genet. 1999;8:899–905.
   PubMed Web of Science ®Google Scholar
• Allingham RR, Wiggs JL, De La Paz MA, et al. Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 1998;39:2288–2295.
   PubMed Web of Science ®Google Scholar
• Jacobson N, Andrews M, Shepard AR, et al. Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor. Hum Mol Genet. 2001;10:117–125.
   PubMed Web of Science ®Google Scholar
• Kim BS, Savinova OV, Reedy MV, et al. Targeted disruption of the myocilin gene (MYOC) suggests that human glaucoma-causing mutations are gain of function. Mol Cell Biol. 2001;21:7707–7713.
   PubMed Web of Science ®Google Scholar
• Wilkinson CH, van der Straaten D, Craig JE, et al. Tonography demonstrates reduced facility of outflow of aqueous humor in myocilin mutation carriers. J Glaucoma. 2003;12:237–242.
   PubMed Web of Science ®Google Scholar
• Souzeau E, Glading J, Keane M, et al. Predictive genetic testing experience for myocilin primary open-angle glaucoma using the Australian and New Zealand registry of advanced glaucoma. Genet Med. 2014;16:558–563.
   PubMed Web of Science ®Google Scholar
• Souzeau E, Tram KH, Witney M, et al. Myocilin predictive genetic testing for primary open-angle glaucoma leads to early identification of at-risk individuals. Ophthalmology. 2017;124:303–309.
   PubMed Web of Science ®Google Scholar
• Jain A, Zode G, Kasetti RB, et al. CRISPR-Cas9-based treatment of myocilin-associated glaucoma. Proc Natl Acad Sci U S A. 2017;114:11199–11204.
   PubMed Web of Science ®Google Scholar
• Gould DB, Reedy M, Wilson LA, et al. Mutant myocilin nonsecretion in vivo is not sufficient to cause glaucoma. Mol Cell Biol. 2006;26:8427–8436.
   PubMed Web of Science ®Google Scholar
• Senatorov V, Malyukova I, Fariss R, et al. Expression of mutated mouse myocilin induces open-angle glaucoma in transgenic mice. J Neurosci. 2006;26:11903–11914.
   PubMed Web of Science ®Google Scholar
• Rezaie T, Child A, Hitchings R, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science. 2002;295:1077–1079.
   PubMed Web of Science ®Google Scholar
• Alward WLM, Kwon YH, Kawase K, et al. Evaluation of optineurin sequence variations in 1,048 patients with open-angle glaucoma. Am J Ophthalmol. 2003;136:904–910.
   PubMed Web of Science ®Google Scholar
• Aung T, Ebenezer ND, Brice G, et al. Prevalence of optineurin sequence variants in adult primary open angle glaucoma: implications for diagnostic testing. J Med Genet. 2003;40:e101.
   PubMed Web of Science ®Google Scholar
• Morton S, Hesson L, Peggie M, et al. Enhanced binding of TBK1 by an optineurin mutant that causes a familial form of primary open angle glaucoma. FEBS Lett. 2008;582:997–1002.
   PubMed Web of Science ®Google Scholar
• Wild P, Farhan H, McEwan DG, et al. Phosphorylation of the autophagy receptor optineurin restricts salmonella growth. Science. 2011;333:228–233.
   PubMed Web of Science ®Google Scholar
• Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223–226.
   PubMed Web of Science ®Google Scholar
• Ramdas WD, Van Koolwijk LM, Ikram MK, et al. A genome-wide association study of optic disc parameters. PLoS Genet. 2010;6:e1000978.
   PubMed Web of Science ®Google Scholar
• Macgregor S, Hewitt AW, Hysi PG, et al. Genome-wide association identifies ATOH7 as a major gene determining human optic disc size. Hum Mol Genet. 2010;19:2716–2724.
   PubMed Web of Science ®Google Scholar
• van Koolwijk LM, Ramdas WD, Ikram MK, et al. Common genetic determinants of intraocular pressure and primary open-angle glaucoma. PLoS Genet. 2012;8:e1002611.
   PubMed Web of Science ®Google Scholar
• Trikha S, Saffari E, Nongpiur M, et al. A genetic variant in TGFBR3-CDC7 is associated with visual field progression in primary open-angle glaucoma patients from Singapore. Ophthalmology. 2015;122:2416–2422.
   PubMed Web of Science ®Google Scholar
• Zode GS, Bugge KE, Mohan K, et al. Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2012;53:1557–1565.
   PubMed Web of Science ®Google Scholar
• Collier R. The downside of genetic screening. Cmaj. 2012;184:862–864.
   PubMed Web of Science ®Google Scholar
• Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science. 2007;317:1397–1400.
   PubMed Web of Science ®Google Scholar
• Abu-Amero KK, Osman EA, Dewedar AS, et al. Analysis of LOXL1 polymorphisms in a Saudi Arabian population with pseudoexfoliation glaucoma. Mol Vis. 2010;16:2805–2810.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim Y. Variations in LOXL1 associated with exfoliation glaucoma do not affect amine oxidase activity. Mol Vis. 2012;18:265–270.
   PubMed Web of Science ®Google Scholar
• Dubey SK, Hejtmancik JF, Krishnadas SR, et al. Lysyl oxidase-like 1 gene in the reversal of promoter risk allele in pseudoexfoliation syndrome. JAMA Ophthalmol. 2014;132:949–955.
   PubMed Web of Science ®Google Scholar
• Grodum K, Heijl A, Bengtsson B. Risk of glaucoma in ocular hypertension with and without pseudoexfoliation. Ophthalmology. 2005;112:386–390.
   PubMed Web of Science ®Google Scholar
• Heijl A, Bengtsson B, Hyman L, et al. Natural history of open-angle glaucoma. Ophthalmology. 2009;116:2271–2276.
   PubMed Web of Science ®Google Scholar
• Fan BJ, Pasquale LR, Rhee D, et al. LOXL1 promoter haplotypes are associated with exfoliation syndrome in a U.S. Caucasian population. Invest Ophthalmol Vis Sci. 2011;52:2372–2378.
   PubMed Web of Science ®Google Scholar
• Schlotzer-Schrehardt U, Pasutto F, Sommer P, et al. Genotype-correlated expression of lysyl oxidase-like 1 in ocular tissues of patients with pseudoexfoliation syndrome/glaucoma and normal patients. Am J Pathol. 2008;173:1724–1735.
   PubMed Web of Science ®Google Scholar
• Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–278.
   PubMed Web of Science ®Google Scholar
• Copin B, Brezin AP, Valtot F, et al. Apolipoprotein E-promoter single-nucleotide polymorphisms affect the phenotype of primary open-angle glaucoma and demonstrate interaction with the myocilin gene. Am J Hum Genet. 2002;70:1575–1581.
   PubMed Web of Science ®Google Scholar
• Tezel G, Yang J, Wax MB. Heat shock proteins, immunity and glaucoma. Brain Res Bull. 2004;62:473–480.
   PubMed Web of Science ®Google Scholar
• Thanos S, Bohm MR, Meyer Zu Horste M, et al. Role of crystallins in ocular neuroprotection and axonal regeneration. Prog Retin Eye Res. 2014;42:145–161.
   PubMed Web of Science ®Google Scholar
• Ban N, Siegfried CJ, Lin JB, et al. GDF15 is elevated in mice following retinal ganglion cell death and in glaucoma patients. JCI Insight. 2017;2(9):e91455.
   Web of Science ®Google Scholar
• Lutjen-Drecoll E, May CA, Polansky JR, et al. Localization of the stress proteins alpha B-crystallin and trabecular meshwork inducible glucocorticoid response protein in normal and glaucomatous trabecular meshwork. Invest Ophthalmol Vis Sci. 1998;39:517–525.
   PubMed Web of Science ®Google Scholar
• Anders F, Teister J, Liu A, et al. Intravitreal injection of beta-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma. PLoS One. 2017;12:e0175451.
   PubMed Web of Science ®Google Scholar
• Anders F, Liu A, Mann C, et al. The small heat shock protein alpha-crystallin b shows neuroprotective properties in a glaucoma animal model. Int J Mol Sci. 2017;18.
   PubMed Web of Science ®Google Scholar
• Korn T. Pathophysiology of multiple sclerosis. J Neurol. 2008;255(Suppl 6):2–6.
   PubMedGoogle Scholar
• D’Andrea MR. Evidence that immunoglobulin-positive neurons in Alzheimer’s disease are dying via the classical antibody-dependent complement pathway. Am J Alzheimers Dis Other Demen. 2005;20:144–150.
   PubMedGoogle Scholar
• Grus FH, Joachim SC, Wuenschig D, et al. Autoimmunity and glaucoma. J Glaucoma. 2008;17:79–84.
   PubMed Web of Science ®Google Scholar
• Joachim SC, Pfeiffer N, Grus FH. Autoantibodies in patients with glaucoma: a comparison of IgG serum antibodies against retinal, optic nerve, and optic nerve head antigens. Graefes Arch Clin Exp Ophthalmol. 2005;243:817–823.
   PubMed Web of Science ®Google Scholar
• Joachim SC, Reichelt J, Berneiser S, et al. Sera of glaucoma patients show autoantibodies against myelin basic protein and complex autoantibody profiles against human optic nerve antigens. Graefes Arch Clin Exp Ophthalmol. 2008;246:573–580.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Liang H. Vaccine for glaucoma, myth or reality? J Fr Ophtalmol. 2006;29(Spec No 2):9–12.
   PubMedGoogle Scholar
• Schwartz M. Modulating the immune system: a vaccine for glaucoma? Can J Ophthalmol. 2007;42:439–441.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Riva I, Gerardi C, et al. Quality of life in glaucoma: a review of the literature. Adv Ther. 2016;33:959–981.
   PubMed Web of Science ®Google Scholar
• Organisation WH. Study protocol for the world health organization project to develop a quality of life assessment instrument (WHOQOL). Qual Life Res. 1993;2:153–159.
   PubMed Web of Science ®Google Scholar
• Power M, Harper A, Bullinger M. The World Health Organization WHOQOL-100: tests of the universality of quality of life in 15 different cultural groups worldwide. Health Psychol. 1999;18:495–505.
   PubMed Web of Science ®Google Scholar
• Skevington SM, Lotfy M, O’Connell KA, et al. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13:299–310.
   PubMed Web of Science ®Google Scholar
• Kurtin PS, Davies AR, Meyer KB, et al. Patient-based health status measures in outpatient dialysis. early experiences in developing an outcomes assessment program. Med Care. 1992;30:MS136–49.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Coleman AL, Yu F, et al. Functional status and well-being in patients with glaucoma as measured by the medical outcomes study short form-36 questionnaire. Ophthalmology. 1998;105:2112–2116.
   PubMed Web of Science ®Google Scholar
• Orta AÖF, Öztürker ZK, Erkul SÖ, et al. The correlation between glaucomatous visual field loss and vision-related quality of life. J Glaucoma. 2015;24:e121–e127.
   PubMed Web of Science ®Google Scholar
• Fenwick EK, O’Hare F, Deverell L, et al. Rasch analysis of the independent mobility questionnaire. Optom Vis Sci. 2016;93:181–187.
   PubMed Web of Science ®Google Scholar
• Walt JG, Rendas-Baum R, Kosinski M, et al. Psychometric evaluation of the glaucoma symptom identifier. J Glaucoma. 2011;20:148–159.
   PubMed Web of Science ®Google Scholar
• Gutierrez P, Wilson MR, Johnson C, et al. Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol. 1997;115:777–784.
   PubMed Web of Science ®Google Scholar
• Odberg T, Jakobsen JE, Hultgren SJ, et al. The impact of glaucoma on the quality of life of patients in Norway. II. Patient response correlated to objective data. Acta Ophthalmol Scand. 2001;79:121–124.
   PubMedGoogle Scholar
• Jampel HD, Frick KD, Janz NK, et al. Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol. 2007;144:238–244.
   PubMed Web of Science ®Google Scholar
• Janz NK, Wren PA, Lichter PR, et al. The collaborative initial glaucoma treatment study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108:1954–1965.
   PubMed Web of Science ®Google Scholar
• Barber BL, Strahlman ER, Laibovitz R, et al. Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology. 1997;104:334–342.
   PubMed Web of Science ®Google Scholar
• Atkinson MJ, Stewart WC, Fain JM, et al. A new measure of patient satisfaction with ocular hypotensive medications: the treatment satisfaction survey for intraocular pressure (TSS-IOP). Health Qual Life Outcomes. 2003;1:67.
   PubMedGoogle Scholar
• Dg D, Ed S, Mj A, et al. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. Eye (Lond). 2006;20:583–590.
   PubMed Web of Science ®Google Scholar
• Wren PA, Musch DC, Janz NK, et al. Contrasting the use of 2 vision-specific quality of life questionnaires in subjects with open-angle glaucoma. J Glaucoma. 2009;18:403–411.
   PubMed Web of Science ®Google Scholar